Genoptix

The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.

The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses. 

The business was acquired by two private investment groups and a management group led by Prometheus Laboratories' former CEO.

Novartis will retain Genoptix's biopharma business, which will be renamed Navigate BioPharma Services.

The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests. 

The test, which relies on multiplex IHC and imaging to calculate a PD-1/PD-L1 interaction score, predicted response in melanoma patients better than PD-L1 testing alone.

NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics today said that it has named Genoptix BioPharma Services as its first partner under its CLIA Certified RNAscope Service Provider program.

Trovagene announced last month that it has granted Novartis' diagnostics laboratory, Genoptix, a worldwide, non-exclusive license to incorporate the nucleophosmin protein marker into research and clinical testing services for acute myelogenous leukemia.

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted to Genoptix a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia.

Pages

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.